Co-Diagnostics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Co-Diagnostics, Inc. (CODX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-31
- Co-Diagnostics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $1.16M, a 68.18% increase from fiscal 2024.
- Co-Diagnostics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $691.80K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $1.16M 10-K · filed 2026-03-31 |
| 2024-12-31 | $691.80K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |